OBJECTIVES: To investigate the biodistribution and specific targeting for tumour necrosis factor (TNF) of a fully human, radiolabelled anti-TNF monoclonal antibody (anti-TNF mAb) in patients with active rheumatoid arthritis (RA). To assess whether this agent is suitable for visualisation of synovitis. METHODS: Ten patients with RA underwent whole body scintigraphy after administration of a tracer-subtherapeutic dose of 100 microg (99m)Tc human anti-TNF mAb. After two weeks, the procedure was repeated to assess the specificity of the radiolabelled antibody for TNF and its sensitivity for changes in inflammation. Therefore, a competition study was performed in five patients, who received excess unlabelled anti-TNF mAb before the tracer dose of (99m)Tc-anti-TNF. Another five patients received 120 mg methylprednisolone two days before the second scintigraphy. RESULTS: Radiolabelled anti-TNF mAb allowed clear visualisation of inflamed joints in patients with active RA with a high specificity. Concomitant administration of excess unlabelled anti-TNF reduced the joint uptake of (99m)Tc-anti-TNF mAb by a median of 25% as a percentage of the injected dose after 24 hours, whereas uptake in liver and spleen remained unchanged. Systemic corticosteroids reduced the disease activity, which was mirrored by a decreased joint uptake of the tracer. The anti-TNF mAb retained its high affinity for TNF alpha after labelling and was cleared from the circulation with an elimination half life of 48 hours. The procedure was well tolerated. CONCLUSIONS: Radiolabelled human anti-TNF mAb allows visualisation of synovitis in patients with RA. Joint accumulation of this agent is partly due to specific TNF targeting and is highly predictive for inflammation.
OBJECTIVES: To investigate the biodistribution and specific targeting for tumour necrosis factor (TNF) of a fully human, radiolabelled anti-TNF monoclonal antibody (anti-TNF mAb) in patients with active rheumatoid arthritis (RA). To assess whether this agent is suitable for visualisation of synovitis. METHODS: Ten patients with RA underwent whole body scintigraphy after administration of a tracer-subtherapeutic dose of 100 microg (99m)Tchuman anti-TNF mAb. After two weeks, the procedure was repeated to assess the specificity of the radiolabelled antibody for TNF and its sensitivity for changes in inflammation. Therefore, a competition study was performed in five patients, who received excess unlabelled anti-TNF mAb before the tracer dose of (99m)Tc-anti-TNF. Another five patients received 120 mg methylprednisolone two days before the second scintigraphy. RESULTS: Radiolabelled anti-TNF mAb allowed clear visualisation of inflamed joints in patients with active RA with a high specificity. Concomitant administration of excess unlabelled anti-TNF reduced the joint uptake of (99m)Tc-anti-TNF mAb by a median of 25% as a percentage of the injected dose after 24 hours, whereas uptake in liver and spleen remained unchanged. Systemic corticosteroids reduced the disease activity, which was mirrored by a decreased joint uptake of the tracer. The anti-TNF mAb retained its high affinity for TNF alpha after labelling and was cleared from the circulation with an elimination half life of 48 hours. The procedure was well tolerated. CONCLUSIONS: Radiolabelled human anti-TNF mAb allows visualisation of synovitis in patients with RA. Joint accumulation of this agent is partly due to specific TNF targeting and is highly predictive for inflammation.
Authors: D M van der Heijde; M A van 't Hof; P L van Riel; L A Theunisse; E W Lubberts; M A van Leeuwen; M H van Rijswijk; L B van de Putte Journal: Ann Rheum Dis Date: 1990-11 Impact factor: 19.103
Authors: M J Abrams; M Juweid; C I tenKate; D A Schwartz; M M Hauser; F E Gaul; A J Fuccello; R H Rubin; H W Strauss; A J Fischman Journal: J Nucl Med Date: 1990-12 Impact factor: 10.057
Authors: P Barrera; L A Joosten; A A den Broeder; L B van de Putte; P L van Riel; W B van den Berg Journal: Ann Rheum Dis Date: 2001-07 Impact factor: 19.103
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: A A den Broeder; L A B Joosten; T Saxne; D Heinegård; H Fenner; A M M Miltenburg; W L H Frasa; L J van Tits; W A Buurman; P L C M van Riel; L B A van de Putte; P Barrera Journal: Ann Rheum Dis Date: 2002-04 Impact factor: 19.103
Authors: M G Steffens; E Oosterwijk; M H Kranenborg; J M Manders; F M Debruyne; F H Corstens; O C Boerman Journal: J Nucl Med Date: 1999-05 Impact factor: 10.057
Authors: Onno J Arntz; Jeroen Geurts; Sharon Veenbergen; Miranda B Bennink; Ben T van den Brand; Shahla Abdollahi-Roodsaz; Wim B van den Berg; Fons A van de Loo Journal: Arthritis Res Ther Date: 2010-04-06 Impact factor: 5.156
Authors: Ingo M Irmler; Thomas Opfermann; Peter Gebhardt; Mieczyslaw Gajda; Rolf Bräuer; Hans P Saluz; Thomas Kamradt Journal: Arthritis Res Ther Date: 2010-11-03 Impact factor: 5.156
Authors: G Malviya; F Conti; M Chianelli; F Scopinaro; R A Dierckx; A Signore Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-24 Impact factor: 9.236
Authors: R Chowdhury; B Ganeshan; S Irshad; K Lawler; M Eisenblätter; H Milewicz; M Rodriguez-Justo; K Miles; P Ellis; A Groves; S Punwani; T Ng Journal: Br J Radiol Date: 2014-03-06 Impact factor: 3.039